| dc.contributor.author | Hizal, M. | |
| dc.contributor.author | Bilgin, B. | |
| dc.contributor.author | Paksoy, N. | |
| dc.contributor.author | Klllçkap, S. | |
| dc.contributor.author | Atcl, M.M. | |
| dc.contributor.author | Kahraman, S. | |
| dc.contributor.author | Keskinklllç, M. | |
| dc.contributor.author | Bilgetekin, Ä. | |
| dc.contributor.author | Ayhan, M. | |
| dc.contributor.author | Tural, D. | |
| dc.contributor.author | Eren, O. | |
| dc.contributor.author | Mustafayev, F.N.A. | |
| dc.contributor.author | Yaman, S. | |
| dc.contributor.author | Tatll, A.M. | |
| dc.contributor.author | Bayram, E. | |
| dc.contributor.author | Kutlu, Y. | |
| dc.contributor.author | Ertürk, I. | |
| dc.contributor.author | Özcan, E. | |
| dc.contributor.author | Gülmez, A. | |
| dc.contributor.author | Korkmaz, M. | |
| dc.contributor.author | Akagündüz, B. | |
| dc.contributor.author | Erdem, D. | |
| dc.contributor.author | Telli, T.A. | |
| dc.contributor.author | Aksoy, A. | |
| dc.contributor.author | Üskent, N. | |
| dc.contributor.author | Iriagac, Y. | |
| dc.contributor.author | Baytemür, N.K. | |
| dc.contributor.author | Aydln, D. | |
| dc.contributor.author | Å akalar, T. | |
| dc.contributor.author | Arak, H. | |
| dc.contributor.author | Selçukbiricik, F. | |
| dc.contributor.author | Ergün, Y. | |
| dc.contributor.author | Korkmaz, T. | |
| dc.contributor.author | Ak, N. | |
| dc.contributor.author | Ünal, C. | |
| dc.contributor.author | Akdeniz, N. | |
| dc.contributor.author | Özgün, M.A. | |
| dc.contributor.author | Öksüzoglu, B. | |
| dc.contributor.author | Yalçln, B. | |
| dc.contributor.author | Öztop, I. | |
| dc.contributor.author | Algln, E. | |
| dc.contributor.author | Sakin, A. | |
| dc.contributor.author | Aydlner, A. | |
| dc.contributor.author | Yumuk, P.F. | |
| dc.contributor.author | Sendur, M.A.N. | |
| dc.date.accessioned | 2022-10-06T12:54:16Z | |
| dc.date.available | 2022-10-06T12:54:16Z | |
| dc.date.issued | 2022 | |
| dc.identifier.issn | 14796694 (ISSN) | |
| dc.identifier.uri | http://hdl.handle.net/11616/72095 | |
| dc.description.abstract | Aims: In this multicenter study, the authors aimed to determine the real-life efficacy and safety of first-line alectinib. Materials & methods: This retrospective trial included advanced-stage, ALK-positive non-small-cell lung cancer patients who were treated with first-line alectinib in terms of ALK-tyrosine kinase inhibitors, regardless of previous chemotherapy. The co-primary end points were progression-free survival both for all patients and for the treatment-naive population. The secondary end points were overall response rate, overall survival, rate of CNS progression and safety. Results & conclusion: A total of 274 patients (n = 177 for treatment-naive patients) were enrolled in the study. The median progression-free survival was 26 and 28.8 months for all patients and the treatment-naive group, respectively. The overall response rate, CNS progression rate and 1-year overall survival ratio were 77.9, 12.4 and 77%. Alectinib is a highly effective therapy with a favorable safety profile. © 2022 Future Medicine Ltd. | |
| dc.source | Future Oncology | |
| dc.title | Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study |
| Dosyalar | Boyut | Biçim | Göster |
|---|---|---|---|
|
Bu öğe ile ilişkili dosya yok. |
|||